TB Manual

References

  1. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases  Society  of  America  Clinical  Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. doi:10.1093/cid/ciw376.
  2. World Health Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. 2017. Licence: CC BY-NC-SA 3.0 IGO.
  3. Johnston JC, Campbell JR, Menzies Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2017;64(9):1211–1220. doi:10.1093/cid/cix121.
  4. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146. doi:10.1371/journal.pmed.1000146.
  5. Gillespie SH. Evolution of drug resistance in Mycobacterium tu- berculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002;46(2):267–274. doi:1128/AAC.46.2.267-274.2002.
  6. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis. 2012;16(6):724–732. doi:5588/ijtld.12.0083.
  7. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20(5):810–814. doi:1128/am.20.5.810-814.1970.
  8. Vernon AA. Chapter 8: Current Standard Treatment. In: Donald PR, van Helden PD, Progress in Respiratory Research. Vol 40. Basel: KARGER; 2011. 61–72.
  9. Forget EJ, Menzies D. Adverse reactions to first-line antituber- culosis drugs. Expert Opin Drug Saf. 2006;5(2):231–249. doi:1517/14740338.5.2.231.
  10. Donald PR, Schaaf Chapter 4: Isoniazid Pharmacokinetics and Efficacy in Adults and Children. In: Donald PR, van Helden PD, eds. Progress in Respiratory Research. Vol 40. Basel: KARGER; 25–31.
  11. Snider Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980;61(4):191–196. doi:10.1016/0041-3879(80)90038-0.
  12. Burman W, Dooley KE, Nuermberger EL. Chapter 3: The Rifamycins: Renewed Interest in an Old Drug Class. In: Donald PR, van Helden PD, Progress in Respiratory Research. Vol Basel: KARGER; 2011. 18–24.
  13. Campbell JR, Trajman A, Cook VJ, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020;20(3):318–329. doi:10.1016/ S1473-3099(19)30575-4.
  14. Laboratory analysis of rifampin/rifapentine products. U.S. Food and Drug https://www.fda.gov/drugs/ drug-safety-and-availability/laboratory-analysis-rifampinrifapent ine-products. Accessed.
  15. Mitchison DA, Zhang Y. Chapter 5: Recent Developments in the Study of Pyrazinamide: An Update. In: Donald PR, van Helden PD, eds. Progress in Respiratory Research. Vol 40. Basel: KARGER; 32–43.
  16. Ezer N, Benedetti A, Darvish-Zargar M, Menzies Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis. 2013;17(4):447–455. doi:10.5588/ijtld.11.0766.
  17. Visser ME, Texeira-Swiegelaar C, Maartens G. The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 2004;8(2):260–262.
  18. McCUNE R, Deuschle K, McDERMOTT W. The delayed appear- ance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc. 1957;76(6):1100–1105.
  19. Chen Z, Liang J-Q, Wang J-H, Feng S-S, Zhang G-Y . Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A  meta-  Tuberculosis  (Edinb)). 2015;95(4):490–496. doi:10.1016/j.tube.2015.03.014.
  20. Lee HW, Lee JK, Kim E, Yim J-J, Lee C-H. The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A  Systematic  Review  and  Meta-Analysis.  PLOS  One. 2016;11(7):e0159827. doi:10.1371/journal.pone.0159827.
  21. Dorman SE, Nahid P, Kurbatova EV, Tuberculosis Trials Consortium, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin  for    N  Engl  J  Med. 2021;384(18):1705–1718. doi:10.1056/NEJMoa2033400.
  22. FDA Drug Safety Communication: FDA advises restricting flu- oroquinolone antibiotic use for certain uncomplicated infections: warns about disabling side effets that can occur U.S. Food and Drug Administration. https://www.fda.gov/media/97602/ download. Accessed February 23, 2022.
  23. Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O. Rifabutin: where do we stand in 2016? J Antimicrob Chemother. 2016;71(7):1759–1771. doi:1093/jac/dkw024.
  24. Pease C, Hutton B, Yazdi F, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis Pharmacoepidemiol Drug Saf. 2018;27(6):557–566. doi:10.1002/pds.4423.
  25. List of drugs for an Urgent Public Health Need. Government of https://www.canada.ca/en/health-canada/services/ drugs-health-products/access-drugs-exceptional-circumstances/ list-drugs-urgent-public-health-need.html. Accessed February 23, 2022.
  26. World Health Organization. Treatment of drug-susceptible tuber- culosis: rapid communication. June 14, 2021
  27. World Health Organization. Concept note: Dose optimization of rifampincin, isoniazid, pyrazinamide and ethambutol in the treat- ment of drug-susceptbile tuberculosis. World Health Organization. https://www.who.int/docs/default-source/hq-tuberculosis/ dose-optimization-concept-note.pdf?sfvrsn=934ab3e2_2. Published Updated 2017. Accessed February 23, 2022.
  28. Romanowski K, Balshaw RF, Benedetti A, et al. Predicting tu- berculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. Thorax. 2019;74(3):291–297.  doi:10.1136/thoraxjnl-2017-211120.
  29. Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary Nat Med. 2018;24(11):1708–1715. doi:10.1038/s41591-018-0224-2.
  30. Horne DJ, Royce SE, Gooze L, et Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. The Lancet Infectious Diseases. 2010;10(6):387– 394. doi:10.1016/S1473-3099(10)70071-2.
  31. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose com- bination antituberculosis therapy: a systematic review and meta- Eur  Respir  J .  2013;42(3):721–732. doi:10.1183/09031936.00180612.
  32. Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Cochrane Infectious Diseases Group, et al. Fixed-dose combi- nations of drugs versus single-drug formulations for treating pulmonary tuberculosis. The Cochrane Database of Systematic Reviews.  2016;2016(5):CD009913.  doi:10.1002/14651858.CD009913.pub2.
  33. Onorato L, Gentile V, Russo A, et Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a sys- tematic review  and  meta-analysis.  Clin  Microbiol  Infect. 2021;27(6):830–837. doi:10.1016/j.cmi.2021.03.031.
  34. Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 1999;3(12):1073–1080.
  35. Flores The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62(3):255–299. doi:10.1177/1077558705275416.
  36. StopTB Partnership. Every Word Counts: Suggested Language And Usage for Tuberculosis Communications. First Edition. 2013. Available at: https://stoptb.org/assets/documents/resources/publications/acsm/LanguageGuide_ForWeb20131110.pdf. Accessed February 23, 2022.
  37. Alipanah N, Jarlsberg L, Miller C, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational PLoS Med. 2018;15(7):e1002595. doi:10.1371/journal.pmed.1002595.
  38. Heuvelings CC, Greve PF, de Vries SG, et al. Effectiveness of service models and organisational structures supporting tuber- culosis identification and management in hard-to-reach popula- tions in countries of low and medium tuberculosis incidence: a systematic review. BMJ Open. 2018;8(9):e019642. doi:10.1136/bmjopen-2017-019642.
  39. Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on tuberculosis treatment: a system- atic Eur Respir J. 2018;51(1):1701596. doi:10.1183/13993003.01596-2017.
  40. Story A, Aldridge RW, Smith CM, et al. Smartphone-enabled video-observed versus directly observed treatment for tubercu- losis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet (London, England). 2019;393(10177):1216–doi:10.1016/S0140-6736(18)32993-3.
  41. Karumbi J, Garner P, Cochrane Infectious Diseases Group Directly observed therapy for treating tuberculosis. The Cochrane Database of Systematic Reviews. 2015;2015(5):CD003343. doi:1002/14651858.CD003343.pub4.
  42. Tian J-H, Lu Z-X, Bachmann MO, Song F-J. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled Int J Tuberc Lung Dis. 2014;18(9):1092–doi:10.5588/ijtld.13.0867.
  43. McKay B, Castellanos M, Ebell M, Whalen CC, Handel A. An attempt to reproduce a previous meta-analysis and a new analysis regarding the impact of directly observed therapy on tuberculosis treatment outcomes. PloS One. 2019;14(5):e0217219. doi:10.1371/journal.pone.0217219.
  44. Müller AM, Osório CS, Silva DR, Sbruzzi G, de Tarso P, Dalcin R. Interventions to improve adherence to tuberculosis treatment: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2018;22(7):731–740. doi:10.5588/ijtld.17.0596.
  45. Hsieh C-J, Lin L-C, Kuo BI-T, Chiang C-H, Su W-J, Shih J-F. Exploring the efficacy of a case management model using DOTS in the adherence of patients with pulmonary J Clin Nurs. 2008;17(7):869–875. doi:10.1111/j.1365-2702.2006.01924.x.
  46. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet (London, England). 1998;352(9137):1340–1343. doi:10.1016/S0140-6736(98)04022-7.
  47. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. Int J Tuberc Lung Dis. 2000;4(6):550–554.
  48. MacIntyre CR, Goebel K, Brown GV, Skull S, Starr M, Fullinfaw A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting. nt J Tuberc Lung Dis. 2003;7(9):848–854.
  49. Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a ran- domised controlled trial in Lancet (London, England). 2001;357(9257):664–669. doi:10.1016/S0140-6736(00)04129-5.
  50. Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Trans R Soc Trop Med Hyg. 1999;93(5):552–557. doi:10.1016/s0035-9203(99)90379-6.
  51. Yin J, Yuan J, Hu Y, Wei X. Association between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. PloS One. 2016;11(3):e0150511. doi:10.1371/journal.pone.0150511.
  52. Zhang H, Ehiri J, Yang H, Tang S, Li Impact of Community-Based DOT on Tuberculosis Treatment Outcomes: A Systematic  Review  and  Meta-Analysis.  PloS  One. 2016;11(2):e0147744. doi:10.1371/journal.pone.0147744.
  53. Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(6):819–826. doi:10.5588/ijtld.15.0803.
  54. Munsiff SS, Nilsen DM, Fujiwara P. Clinical Policies and New York City Department of Health and Mental Hygiene, New York City Department of Health and Mental Hygiene, Bureau of Tuberculosis Control. 2008. http://www1.nyc.gov/site/doh/health/health-topics/tb-hosp-manual.page.
  55. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston Long-term all-cause mortality in people treat- ed for tuberculosis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2019;19(10):1129–1137. doi:10.1016/S1473-3099(19)30309-3.
  56. Basham CA, Smith SJ, Romanowski K, Johnston Cardiovascular morbidity and mortality among persons diagnosed with tuber- culosis: A systematic review and meta-analysis. PloS One. 2020;15(7):e0235821. doi:10.1371/journal.pone.0235821.
  57. Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration; International Review  of  Thoracic  Diseases.  2013;86(1):76–85.  doi:10.1159/000350917.
  58. Quaife M, Houben RMGJ, Allwood B, et al. Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. Lancet Respir Med. 2020;8(4):332–333. doi:1016/S2213-2600(20)30039-4.
  59. Vega V, Rodríguez S, Van der Stuyft P, Seas C, Otero L. Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and Thorax. 2021;76(5):494–502. doi:10.1136/thoraxjnl-2020-215449.
  60. Nunn AJ, Phillips PPJ, Mitchison Timing of relapse in short-course chemotherapy trials for tuberculosis. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 2010;14(2):241–242.
  61. Basham CA, Karim ME, Cook VJ, Patrick DM, Johnston Post-tuberculosis mortality risk among immigrants to British Columbia, Canada, 1985-2015: a time-dependent Cox regression analysis of linked immigration, public health, and vital statistics data. Can J Public Health. 2021;112(1):132–141. doi:10.17269/s41997-020-00345-y.
  62. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015;32:138–146. doi:1016/j.ijid.2014.12.016.
  63. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018;27(147):170077. doi:1183/16000617.0077-2017.
  64. Migliori GB, Marx FM, Ambrosino N, et Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021;25(10):797–813. doi:10.5588/ijtld.21.0425.
  65. Simonsen DF, Farkas DK, Søgaard M, Horsburgh CR, Sørensen HT, Thomsen RW. Tuberculosis and risk of cancer: a Danish nationwide cohort study. Int J Tuberc Lung Dis. 2014;18(10):1211–doi:10.5588/ijtld.14.0161.
  66. Duko B, Bedaso A, Ayano G. The prevalence of depression among patients with tuberculosis: a systematic review and meta-analysis. Ann Gen Psychiatry. 2020;19:30. doi:1186/s12991-020-00281-8.
  67. Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis – a systematic review. BMC Public Health. 2008;8:289. doi:1186/1471-2458-8-289.

Switch To: Français

Previously
ORCID
Up Next
Chapter 6: Tuberculosis preventive treatment in adults